Investors of Rocket Pharmaceuticals file lawsuit claiming securities fraud.

Rocket Pharmaceuticals (RCKT) investors who made purchases between February 27, 2025, and May 26, 2025, are being reminded by Rosen Law Firm of the upcoming lead plaintiff deadline on August 11, 2025. Individuals who acquired RCKT securities within this timeframe might have a chance to receive compensation without incurring any out-of-pocket fees or expenses through a contingency fee agreement. Those interested in participating in the class action can do so by accessing the website provided by Rosen Law Firm or by contacting Phillip Kim, Esq., at the telephone number specified.

The legal notice serves as a reminder to shareholders about the upcoming deadline to be appointed as the lead plaintiff in the class action lawsuit. This lawsuit alleges that Rocket Pharmaceuticals made false and/or misleading statements and failed to disclose important information concerning the company’s business, operational, and compliance policies during the specified period. Investors who held RCKT securities within that timeframe are encouraged to participate in the case to potentially recover financial losses incurred due to these alleged actions.

The lead plaintiff appointment process is crucial in securities class actions as it allows the court to select a representative plaintiff who can act on behalf of all class members in pursuing the case against the defendant. By becoming the lead plaintiff, an investor takes an active role in the litigation process, works closely with legal counsel, and represents the best interests of all affected shareholders.

During the specified period, it is alleged that Rocket Pharmaceuticals engaged in wrongful conduct that impacted its business operations and financial performance. Investors who suffered losses as a result of these alleged actions now have the opportunity to seek compensation through the class action lawsuit. By participating in the case, shareholders could potentially recover damages and hold the company accountable for any misleading statements or omissions that may have influenced investment decisions.

The lead plaintiff deadline on August 11, 2025, is fast approaching, and investors who wish to be considered for this role should take immediate action to ensure their eligibility. By joining the class action, shareholders can seek to recover financial losses without having to pay fees or costs upfront, thanks to the contingency fee arrangement offered by Rosen Law Firm. To participate in the lawsuit and potentially obtain compensation, interested parties are urged to contact the firm or visit the specified website to submit their information and be considered for the lead plaintiff position.